文献速递腹部泌尿生殖CT

转移性肾细胞癌患者早期光谱双层探测器CT参数下降作为有利的影像生物标志物

Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma.
PubMed 文献 · Eur Radiol · 2022-05-05

本研究纳入转移性肾细胞癌患者,在基线和治疗1个月后行双层探测器光谱CT扫描,评估靶病灶的碘浓度、有效原子序数和CT值相对变化与生存及治疗反应的关系。结果显示,治疗1个月时碘浓度和有效原子序数下降幅度最大者总生存更好,有效原子序数下降幅度最大者治疗反应更高;靶病灶最长径之和缩小≥30%与结局无关。

要点

  • 治疗1个月时靶病灶碘浓度和有效原子序数下降幅度大,与总生存改善相关。
  • 治疗1个月时有效原子序数下降幅度大,与客观治疗反应更高相关。
  • 治疗1个月时靶病灶最长径之和缩小≥30%与生存或治疗反应无显著关联。

核心结论

  • 治疗1个月时靶病灶碘浓度和有效原子序数的早期下降与转移性肾细胞癌患者更好的结局相关,该信息可能让医生和患者对治疗策略更安心。

研究设计与样本

  • 研究论文;基线和治疗1个月后行双层探测器光谱CT扫描,重建常规CT和光谱CT系列;基线纳入115例、1个月时纳入104例转移性肾细胞癌患者。

诊断标准与关键数值

  • 联合RECIST v1.1靶病灶的碘浓度中位数从2.3 mg/ml降至1.2 mg/ml(p < 0.001)。
  • 联合靶病灶的有效原子序数中位数从8.5降至8.0(p < 0.001)。
  • 联合靶病灶的CT值中位数从86.0 HU降至64.0 HU(p < 0.001)。
  • 多因素校正后,碘浓度下降幅度最大与总生存改善相关(HR 0.47,95% CI:0.24-0.94,p = 0.033)。
  • 多因素校正后,有效原子序数下降幅度最大与总生存改善(HR 0.43,95% CI:0.21-0.87,p = 0.019)及治疗反应更高(OR = 2.79,95% CI:1.12-6.94,p = 0.027)相关。

临床应用与阅片要点

  • 作者认为,治疗1个月时碘浓度和有效原子序数的早期下降可作为转移性肾细胞癌的独立影像生物标志物,用于提示更好的总生存。
  • 作者认为,治疗1个月时有效原子序数的早期下降可作为独立影像生物标志物,用于提示更好的治疗反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To associate the early change in DL-CT parameters and HU with survival outcomes and treatment response in patients with metastatic renal cell carcinoma (mRCC).

METHODS: DL-CT scans were performed at baseline and after 1 month of checkpoint immunotherapy or tyrosine kinase inhibitor therapy. Scans were reconstructed to conventional CT and DL-CT series, and used for assessment of HU, iodine concentration (IC), and the effective atomic number (Zeffective) in the combined RECISTv.1.1 target lesions. The relative changes, defined as ΔIC(combined), ΔZeffective(combined), and ΔHU(combined), were associated with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). The reduction in the sum of diameters of target lesions ≥ 30% after 1 month was associated with OS, PFS, and ORR.

RESULTS: Overall, 115 and 104 mRCC patients were included at baseline and 1 month, respectively. Median IC(combined) decreased from 2.3 to 1.2 mg/ml (p < 0.001), Zeffective(combined) from 8.5 to 8.0 (p < 0.001), and HU(combined) from 86.0 to 64.00 HU (p < 0.001). After multivariate adjustments, the largest reductions in ΔIC(combined) (HR 0.47, 95% CI: 0.24-0.94, p = 0.033) and ΔZeffective(combined) (HR = 0.43, 95% CI: 0.21-0.87, p = 0.019) were associated with favorable OS; the largest reduction in ΔZeffective(combined) was associated with higher response (OR = 2.79, 95% CI: 1.12-6.94, p = 0.027). The largest reduction in ΔHU(combined) was solely associated with OS in univariate analysis (HR 0.45, 95% CI: 0.23-0.91). Reduction in SOD ≥ 30% at 1 month was not associated with outcomes (p > 0.075).

CONCLUSIONS: Early reductions at 1 month in ΔIC(combined) and ΔZeffective(combined) are associated with favorable outcomes in patients with mRCC. This information may reassure physicians and patients about treatment strategy.

KEY POINTS: • Early reductions following 1 month of therapy in spectral dual-layer detector CT-derived iodine concentration and the effective atomic number (Zeffective) are independent biomarkers for better overall survival in patients with metastatic renal cell carcinoma. • Early reduction after 1 month of therapy in the effective atomic number (Zeffective) is an independent imaging biomarker for better treatment response metastatic renal cell carcinoma.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Drljevic-Nielsen, Mains, Thorup, et al. Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma. Eur Radiol. 2022. PMID: 35511260. doi:10.1007/s00330-022-08793-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。